Skye Bioscience Inc
NASDAQ:SKYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-31.95 (3 536% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.6 | $0.93 |
0%
|
| Industry Average | 19.1 | $-31.95 |
-3 536%
|
| Country Average | 22.9 | $-38.2 |
-4 207%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$23.8m
|
/ |
Jan 2026
$-55.9m
|
= |
|
|
$23.8m
|
/ |
Dec 2026
$-34.5m
|
= |
|
|
$23.8m
|
/ |
Dec 2027
$-40.3m
|
= |
|
|
$23.8m
|
/ |
Dec 2028
$-48.9m
|
= |
|
|
$23.8m
|
/ |
Dec 2029
$-55.1m
|
= |
|
|
$23.8m
|
/ |
Dec 2030
$-30.6m
|
= |
|
|
$23.8m
|
/ |
Dec 2031
$-22.5m
|
= |
|
|
$23.8m
|
/ |
Dec 2032
$-4.1m
|
= |
|
|
$23.8m
|
/ |
Dec 2033
$14.4m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Skye Bioscience Inc
NASDAQ:SKYE
|
31m USD | -0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
